((自动化翻译由路透提供，请见免责声明 ))
10月1日 - ** IGM生物科学公司 股价盘前下跌约26%，报12美元
** IGMS 周一宣布更换首席执行官 (link)，并表示将尽量减少癌症药物研究方面的支出
** 摩根大通将公司股票评级从 "中性 "下调至 "减持
** 摩根大通将该公司的股票评级从 "中性 "下调至 "减持"。
** 摩根大通认为，IGMS通过重新调整药物管线，"延长了 "首个商业产品的上市时间，并称该公司2027年上半年的现金流似乎 "过于激进"。
** 包括 JPM 在内的至少 4 家券商下调了股票的预测价格
** 覆盖 IGMS 的 10 家券商中，有 6 家将其股票评级为 "买入 "或更高，3 家为 "持有"，1 家为 "卖出"--LSEG
** 截至上次收盘，IGMS 的股价今年以来几乎翻了一番
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.